| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/09/2011 | WO2011069094A1 Methods of administering pirfenidone therapy |
| 06/09/2011 | WO2011069089A1 Pirfenidone therapy and inducers of cytochrome p450 |
| 06/09/2011 | WO2011068226A1 Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
| 06/09/2011 | WO2011068211A1 2-pyridone compounds |
| 06/09/2011 | WO2011068187A1 Quinazoline derivatives |
| 06/09/2011 | WO2011068150A1 Glucagon-like peptide-1 secretion enhancer |
| 06/09/2011 | WO2011068149A1 Cholecystokinin secretion enhancer |
| 06/09/2011 | WO2011068136A1 Pharmaceutical agent comprising antibody capable of binding specifically to ganglioside gd3 |
| 06/09/2011 | WO2011066683A1 Pharmaceutical composition for treating hepatitis |
| 06/09/2011 | WO2010143168A3 Compounds useful for treating cancer |
| 06/09/2011 | US20110136915 Rapid dissolution formulation of a calcium receptor-active compound |
| 06/09/2011 | US20110136906 Use of hydroxyoleic acid and related compounds in the manufacture of drugs |
| 06/09/2011 | US20110136812 Solubilized topoisomerase poisons |
| 06/09/2011 | US20110136775 Methods for Treating Injury Associated with Exposure to an Alkylating Species |
| 06/09/2011 | US20110136746 Kallikrein-Binding "Kunitz Domain" Proteins and Analogues Thereof |
| 06/09/2011 | US20110136745 Method of selecting soybeans with enhanced bioactivity and compositions for reducing cancer cell viability |
| 06/09/2011 | US20110136743 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 06/09/2011 | US20110136739 Use of S1P Receptor Agonists in Heart Diseases |
| 06/09/2011 | US20110135763 Antiseptic formulation especially for prevention of complications associated with skin burns |
| 06/09/2011 | US20110135759 Stem cell/endothelial progenitor cell mobilization by nutraceutical formulations |
| 06/09/2011 | US20110135740 Tissue substitutes comprising stem cells and reduced ceria |
| 06/09/2011 | US20110135729 Methods for Controlling Heat Generation of Magnetic Nanoparticles and Heat Generating Nanomaterials |
| 06/09/2011 | US20110135718 Viral particle-like structure in physiological conditions, and method of forming it |
| 06/09/2011 | US20110135684 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro |
| 06/09/2011 | US20110135606 Test systems for the analysis of polypeptides and cells adhering to silicones |
| 06/09/2011 | US20110135596 Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof |
| 06/09/2011 | US20110135577 Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF |
| 06/09/2011 | CA2782727A1 2-pyridone compounds |
| 06/08/2011 | EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/08/2011 | EP2330197A2 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
| 06/08/2011 | EP2330127A2 Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same |
| 06/08/2011 | EP2330121A2 Binding moieties based on Shark IgNAR domains |
| 06/08/2011 | EP2330120A2 Binding moieties based on Shark IgNAR domains |
| 06/08/2011 | EP2330104A1 Glucosyltransferase inhibitor comprising epigallocatechin gallate polymer as active ingredient |
| 06/08/2011 | EP2330100A1 An improved process for preparation of taxane derivatives |
| 06/08/2011 | EP2329850A2 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 06/08/2011 | EP2329847A2 Use of an antibody or an immunotoxin that selectively binds to CD123 to impair hematologic cancer progenitor cells |
| 06/08/2011 | EP2329823A1 Method for improving absorbability of preparation, and preparation having improved absorbability |
| 06/08/2011 | EP2329822A1 Compositions and methods of treatment of cancer |
| 06/08/2011 | EP2328902A1 Pyrazolo [5,1-b]oxazole derivatives as crf1 antagonists |
| 06/08/2011 | EP2328892A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 06/08/2011 | EP2328889A1 Acetyl pyrrolidinyl indole derivative |
| 06/08/2011 | EP2328576A1 Use of nmda activity enhancers to treat hypersomnia, reduced wakefulness or reduced vigilance |
| 06/08/2011 | EP1757610B1 Condensed pyrimidine derivative and xanthine oxidase inhibitor |
| 06/08/2011 | EP1502599B1 Use of mutated VEGF for antiangiogenic therapy |
| 06/08/2011 | EP1479397B1 2,4,6-triamino-1,3,5-triazine derivative |
| 06/08/2011 | EP1434579B1 Imidazole derivatives as antiinflammatory agents |
| 06/08/2011 | EP1431293B1 Water-soluble phenylpyridazine derivatives and drugs containing the same |
| 06/08/2011 | EP1392255B1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 06/08/2011 | EP1300407B2 Carbamates derived from arylalkylamines |
| 06/08/2011 | EP1078093B1 Vaccines, immunotherapeutics and methods for using the same |
| 06/08/2011 | EP1069821B1 Method of controlling proliferation and differentiation of stem and progenitor cells |
| 06/08/2011 | CN1931336B Chinese medicine composition and its preparation process |
| 06/08/2011 | CN1890224B 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose)polymerase inhibitors |
| 06/08/2011 | CN1700918B N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| 06/08/2011 | CN102089303A Nitrogenated heterocyclic compound |
| 06/08/2011 | CN102089302A Nitrogenated bicyclic heterocyclic compound |
| 06/08/2011 | CN102089291A Cyclopentylacrylic acid amide derivative |
| 06/08/2011 | CN102089283A Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group |
| 06/08/2011 | CN102089281A Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 06/08/2011 | CN102089009A Conjugated Vi saccharides |
| 06/08/2011 | CN102088985A Intestinal environment-improving agent |
| 06/08/2011 | CN102088978A Ameliorating or therapeutic agent for dyslipidemia |
| 06/08/2011 | CN102088871A Nutritional composition containing oligosaccharide mixture |
| 06/08/2011 | CN102086182A Petasites tatewakianus Kitam. extract as well as preparation method and application thereof |
| 06/08/2011 | CN102085344A Aplotaxis carminative sustained-release preparation and preparation method thereof |
| 06/08/2011 | CN102085298A Medicament for treating swine high fever |
| 06/08/2011 | CN102085290A Preparation method and application of compound rhodiola rosea preparation |
| 06/08/2011 | CN102085285A Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae |
| 06/08/2011 | CN102085031A Traditional Chinese medicine sachet and preparation method thereof |
| 06/08/2011 | CN101385858B Purified PEG human growth hormone conjugates and preparation thereof |
| 06/08/2011 | CN101337932B Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| 06/08/2011 | CN101128578B Method of inducing differentiation of skeletal muscle cell |
| 06/08/2011 | CN101080404B Pyrimidinylisoxazol derivative |
| 06/07/2011 | US7956187 Method for decreasing opioid metabolism |
| 06/07/2011 | US7956093 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins |
| 06/07/2011 | US7956084 Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 |
| 06/07/2011 | US7956075 Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. |
| 06/07/2011 | US7956072 Agent for repairing corneal sensitivity containing amide compound |
| 06/07/2011 | US7956053 Inhibitors of tyrosine kinases |
| 06/07/2011 | US7956040 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 06/07/2011 | US7956036 Polypeptide and DNA thereof useful as a neovascular marker |
| 06/07/2011 | US7955626 Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester |
| 06/07/2011 | US7955594 Polymers with structure-defined functions |
| 06/07/2011 | CA2567306C Radiosensitizer |
| 06/07/2011 | CA2555824C Fused-ring 4-oxopyrimidine derivative |
| 06/07/2011 | CA2505545C Indolyl derivatives |
| 06/07/2011 | CA2490573C Improved transdermal delivery system |
| 06/07/2011 | CA2484816C Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds |
| 06/07/2011 | CA2483164C Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 06/07/2011 | CA2466580C Orodispersible tablets containing fexofenadine |
| 06/07/2011 | CA2456977C Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 06/07/2011 | CA2455774C Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain |
| 06/07/2011 | CA2442971C Chemotherapeutic induction of egr-1 promoter activity |
| 06/07/2011 | CA2442194C Novel peptide sy |
| 06/07/2011 | CA2441845C Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 06/07/2011 | CA2423868C Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| 06/07/2011 | CA2423190C Angiogenic agents and their uses |
| 06/07/2011 | CA2405705C The treatment of respiratory diseases |